Valuation: Mount Magnet South Ltd

Market Cap 54.32M 37.93M 33.14M 30.59M 28.19M 53.14M 3.65B 366M 144M 1.79B 142M 139M 6.16B P/E 2026 *
-2.04x
P/E 2027 * -2.2x
Enterprise Value 54.32M 37.93M 33.14M 30.59M 28.19M 53.14M 3.65B 366M 144M 1.79B 142M 139M 6.16B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.66%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 37 2015-12-31
Director of Finance/CFO 35 2024-02-28
Chief Tech/Sci/R&D Officer - 2022-12-31
Director TitleAgeSince
Chairman 52 2023-10-31
Director/Board Member 60 2023-10-31
Director/Board Member 37 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.24%-1.54%+52.85%+71.85% 53.83B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.77%-2.62%+40.54%+184.05% 25.95B
Weighted average by Cap. -2.80%-2.36%+39.55%+143.13%

Financials

2026 *2027 *
Net sales - -
Net income -24.91M -17.4M -15.2M -14.03M -12.93M -24.37M -1.68B -168M -65.95M -821M -65.34M -63.9M -2.82B -24.89M -17.38M -15.19M -14.01M -12.92M -24.35M -1.67B -167M -65.88M -820M -65.26M -63.83M -2.82B
Net Debt - -
Logo Mount Magnet South Ltd
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Employees
-